Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948688 · ClinicalTrials.gov registry record · Phase 1
Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00948688: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00948688 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00948688, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The durg vorinostat (Zolinza) is a type of drug called an histone deacetylase (HDAC) inhibitor. It inhibits a group of enzymes called histone deacetylases. These enzymes help cancer cells survive. By inhibiting these enzymes, vorinostat helps kill cancer cells. In this research study vorinostat will be given along with radiation therapy and the drug 5-FU. This is the first research study in which vorinostat will be given along with radiation therapy and 5-FU. The purpose of this research study is to find the highest dose of vorinostat that can be given safely along with radiation therapy and 5-FU. The investigators will also begin to get information about whether vorinostat combined with radiation and 5-FU may help to treat pancreatic cancer.
Interventions
- RADIATION Radiation therapy
- DRUG 5-FU
- DRUG Vorinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-08 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00948688
The ClinicalTrials.gov registry entry for NCT00948688 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation therapy is the first listed.
NCT00948688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00948688 about?
NCT00948688 is a clinical study titled "Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas". The durg vorinostat (Zolinza) is a type of drug called an histone deacetylase (HDAC) inhibitor. It inhibits a group of enzymes called histone deacetylases. These enzymes help cancer cells survive. By inhibiting these enzymes, vorinostat helps kill cancer cells. In this research study vorinostat will...
What is the current status of trial NCT00948688?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2009-08. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00948688?
The interventions under investigation include: Radiation therapy (RADIATION), 5-FU (DRUG), Vorinostat (DRUG).
Who is sponsoring clinical trial NCT00948688?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.